Vaxcyte, Inc. (PCVX)

業務介紹

瓦克斯特公司(Vaxcyte, Inc.)是一家處於臨床階段的生物技術疫苗公司,開發新型蛋白質疫苗以預防或治療細菌性傳染性疾病。其主要疫苗候選藥物是VAX-24,這是一種24價肺炎球菌結合疫苗,正處於1/2期臨床試驗階段,用於治療侵襲性肺炎球菌病和肺炎。該公司還開發VAX-XP以保護對抗新興菌株並解決抗生素耐藥性問題;VAX-A1,一種旨在治療A族鏈球菌的結合疫苗候選藥物;以及VAX-PG,一種針對牙周炎關鍵病原體的新型蛋白質疫苗候選藥物。該公司曾名為SutroVax, Inc.,於2020年5月更名為Vaxcyte, Inc.。Vaxcyte, Inc.於2013年註冊成立,總部位於加州聖卡洛斯。



Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

公司網址

https://vaxcyte.com